Humanigen (OTCQB:HGEN +37.3%) announces
data on the first clinical use of lenzilumab, the proprietary
Humaneered anti-human granulocyte macrophage-colony stimulating
factor, in 12 COVID-19 patients.
Patients showed rapid clinical improvement with a
median time to recovery of five days, median time to discharge of five
days and 100% survival to the data cut-off date.
Rapid improvement in oxygenation, temperature,
inflammatory cytokines and key hematological parameters consistent with
improved clinical outcomes was also observed.
No treatment-emergent adverse events were attributable to lenzilumab and it was well-tolerated.
https://seekingalpha.com/news/3583023-humanigen-rallies-on-positive-lenzilumab-data-in-covidminus-19-patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.